The major COVID variants we've seen so far and which one to look out for right now
Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...
pharmaphorum3d
New COVID-19 jabs approved by FDA for 2024-25 season
The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...
pharmaphorum2d
Pfizer, BioNTech submit to FDA for Covid vaccine in under 5s
The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...
Hosted on MSN4d
Should Kids Get the COVID-19 Vaccine?
Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... but they're not immune to the virus. "At ...
Fort McMurray Today6d
Do COVID-19 boosters still make sense? What to know about the latest vaccine rollout
The strains currently circulating are mostly descendants of KP.2, meaning the vaccines should be “a pretty good match,” Shapiro said. With a rapidly evolving virus, it’s never going to be a perfect ...
Peptide Therapeutics Market Size to Surpass USD 76.11 Billion by 2033 | Straits Research
The global peptide therapeutics market size was valued at USD 45.43 billion in 2023. It is projected to reach from USD 48.11 ...
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Vermont Business Magazine1d
VDH: COVID cases up, but serious cases remain low
The number of COVID cases increased last week to 146. Cases had been falling in April and May and were as low as 31 at the ...